Report #2848947

Received Jul 8, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
COVID19	COVID19 (COVID19 (PFIZER-BIONTECH))	PFIZER\BIONTECH	1	—	—

Symptoms (1)

Epistaxis

Symptom narrative

severe and persistent nosebleeds; This is a spontaneous report received from a Consumer or other non HCP, Program ID. A female patient received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: EPISTAXIS (medically significant), outcome "unknown", described as "severe and persistent nosebleeds". Additional information: The patient reported experiencing severe and persistent nosebleeds after receiving a Pfizer COVID-19 vaccine. The patient inquired about related studies and side effects. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.